<DOC>
	<DOCNO>NCT01802138</DOCNO>
	<brief_summary>Activated T cell manufacture vitro T cell expansion autologous T cell . We design study determine feasibility safety Activated T-lymphocyte cell therapy refractory/relapsed neuroblastoma patient .</brief_summary>
	<brief_title>A Pilot Study Activated T Cell Therapy Refractory/Relapsed Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>Informed consent Age 21 year younger Histologically confirm neuroblastoma Progressive disease standard treatment relapse patient ECOG scale ( ECOGPS ) â‰¤2 Expected survival least 3 month Patients autoimmune disease Patients immunodeficiency Other malignancy 5 year prior study Severe organ dysfunction Severe allergic disease Severe psychiatric disorder Pregnancy lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>refractory/relapsed neuroblastoma patient</keyword>
</DOC>